Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/136057USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO 30.06.2022
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No PCT/EP2021/085935 Applicant PROBIOGEN AG Inventor BAKACS, Tibor
The present invention relates to a birnavirus for use in the treatment or prevention of cancer. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment or prevention of cancer. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment or prevention of cancer.
2.20220203088Methods And Compositions For Using Alternating Electric Fields In Gene Therapy
US 30.06.2022
Int.Class A61N 1/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1Electrotherapy; Circuits therefor
18Applying electric currents by contact electrodes
32alternating or intermittent currents
Appl.No 17559228 Applicant NOVOCURE GMBH Inventor Tali Voloshin-Sela

Disclosed are compositions for methods of transporting of a vector, therapeutic, detectable, or combination thereof across a cell membrane of a cell. Also disclosed are methods of detecting and/or treating a tumor or cancer cell using a vector, therapeutic, detectable, or combination thereof either alone or in combination with applying alternating electric fields.

3.WO/2022/140560IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS ENCLOSING RNA
WO 30.06.2022
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2021/064887 Applicant FLAGSHIP PIONEERING INNOVATIONS V, INC. Inventor HAJJAR, Roger Joseph
This invention relates generally to compositions for making anellovectors and uses thereof.
4.WO/2022/135683USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF A DISEASE CAUSED BY A NIDOVIRUS
WO 30.06.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2020/087550 Applicant PROBIOGEN AG Inventor KOVESDI, Imre
The present invention relates to a birnavirus for use in the treatment of a disease caused by a nidovirus. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment of a disease caused by a nidovirus. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment of a disease caused by a nidovirus.
5.20220204574PRODUCTION OF LARGE-SIZED QUASIDYSTROPHINS USING OVERLAPPING AAV VECTORS
US 30.06.2022
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No 17593285 Applicant GENETHON Inventor Isabelle RICHARD

The present invention concerns a quasidystrophin (QD) having the structure CH1CH2H1R1R2R3H2R8R9 in its N-terminal part and advantageously further comprising the R16 and R17 rod domains, as well as the dual AAV vector system which allows producing it.

6.WO/2022/133970COMPOSITION COMPRISING ONCOLYTIC VIRUS AND APPLICATION THEREOF IN TUMOR TREATMENT
WO 30.06.2022
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/CN2020/139196 Applicant SUZHOU INSTITUTE OF SYSTEMS MEDICINE Inventor YANG, Heng
Provided is a composition comprising an oncolytic virus and an application thereof in tumor treatment. Specifically, provided are a composition comprising an oncolytic virus, an application of the composition in the preparation of a drug for killing dysplastic cells, inducing and promoting anti-tumor immune responses or eliminating immunosuppression in a tumor tissue microenvironment, an application in the preparation of a drug for treating a patient suffering from a tumor, and a method for slow and sustained killing of dysplastic cells. The composition comprising an oncolytic virus can reduce or eliminate the expression level of the BACH1 gene, thereby promoting the immunogenicity produced by the oncolytic virus, promoting the infiltration of T lymphocytes, increasing anti-tumor immune responses, and inhibiting tumor growth.
7.WO/2022/139490NOVEL MODIFIED REOVIRUS AND USE THEREOF
WO 30.06.2022
Int.Class A61K 35/765
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
765Reovirus; Rotavirus
Appl.No PCT/KR2021/019663 Applicant VIROCURE, INC. Inventor YOO, Haeng Jun
The present invention relates to a modified reovirus and use thereof, and has been completed by confirming that a novel modified reovirus derived from a wild-type reovirus not only has an excellent anticancer effect on various cancers, including rare cancers, but can also enhance the effect of cancer immunotherapy agents. Particularly, it was confirmed that the modified reovirus according to the present invention significantly reduced the cell viability of all cancer cell lines when used to treat various types of cancer cells, including rare cancers such as melanoma and tongue cancer, and in particular, had an excellent anticancer effect even on taxane-based anticancer drug-resistant cancer cell lines. Furthermore, the modified reovirus according to the present invention exhibited a dose-dependent anticancer effect even in melanoma, bladder cancer and oral cancer mouse models regardless of administration routes, and the anticancer effect was shown to be further increased upon repeated administration or alternate administration with a wild-type reovirus. In particular, it was confirmed that the modified reovirus according to the present invention exhibited a synergistic anticancer effect when used in combination with an immune checkpoint inhibitor. Therefore, the modified reovirus according to the present invention is expected to be effectively used as a new anticancer therapy for treating rare cancers and the like and as a drug used in combination with a cancer immunotherapy agent.
8.20220202916COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING GLYCOGEN STORAGE DISEASE TYPE III
US 30.06.2022
Int.Class A61K 38/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
47acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Appl.No 17560595 Applicant Duke University Inventor Baodong Sun

Adult form glycogen storage disease type III (GSD III) is an orphan neuromuscular disorder caused by a deficiency of glycogen debranching enzyme. Long-term complications include progressive liver fibrosis, hepatic failure, and end-stage liver cirrhosis, and progressive muscle myopathy. Presently, there are no clinically approved therapies or cures for GSD III. Disclosed herein are compositions for and methods of treating and/or preventing GSD III disease progression.

9.WO/2022/133532COMPOSITIONS FOR THE TOPICAL DELIVERY OF PHAGE
WO 30.06.2022
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/AU2021/051537 Applicant PHAGE CONSULTING PTY LTD. Inventor CHAN, Kim
The present invention provides compositions for the topical delivery of bacteriophage, including compositions which may be formulated for administration by spraying, and methods for the preparation of said compositions. The compositions and methods described herein may find application in, but are not limited to, the topical delivery of therapeutic bacteriophage. Said compositions comprise at least one non-ionic polymer selected from the group consisting of polyvinyl alcohol (PVA), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), polyethylene oxide (PEO), hydroxypropyl methylcellulose (HPMC), agarose and guar gum, preferably polyethylene oxide (PEO), polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP).
10.WO/2022/139440NOVEL RECOMBINANT MYXOMA VIRUS AND USE THEREOF
WO 30.06.2022
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No PCT/KR2021/019577 Applicant VIROCURE, INC. Inventor YOO, Haeng Jun
The present invention relates to a recombinant Myxoma virus and a use thereof and has been achieved by finding that a recombinant Myxoma virus having multiple anti-cancer genes introduced thereinto can not only exhibit an excellent anticancer effect, but also augment the effect of cancer immunotherapy. The Myxoma virus selected in the present invention, which is an anticancer virus with tumor selectivity, does not cause any infection symptoms except for in rabbits and as such, has the advantage of causing no diseases in humans. Therefore, the Myxoma virus can be administered intravenously at a high dose for a long period of time and activates dendritic cells when administered into the body, thus exhibiting the effect of augmenting immune functions. The present inventors prepared a recombinant Myxoma virus by introducing single or multiple anticancer genes into the genome of Myxoma virus and found that the recombinant virus exhibited more potent anticancer effects than a wild-type virus. Particularly when used in combination with an immune checkpoint inhibitor, the recombinant Myxoma virus according to the present invention was found to have an enhanced anticancer effect of the drug and active anticancer immune functions for a long period of time. Therefore, the recombinant Myxoma virus according to the present invention is expected to be utilized as a novel anticancer therapy for incurable cancer, etc. and as a drug in combination with an immune therapy.